Monthly Archives: May 2017

The most prevalent gauge of efficacy in the study of fibromyalgia drugs is — no surprise here — pain relief. But analgesic effect alone is not a sufficient measure in the eyes of the FDA, which seeks evidence of overall benefit and improvement in patient function when evaluating treatments for a condition commonly associated withRead more

DURHAM, N.C., MAY 23, 2017 — Interleukin-2, interferon, and other immune-modulating agents have long been used to treat some solid malignancies, but their efficacy is generally limited to immunogenic cancers such as melanoma and kidney cancer. Until now. Today, multiple immuno-oncology pathways are under development, and we’ll explore this promising trend in a webinar onRead more

Dr. Thomas Laage,  Director, Product Development Consulting and Regulatory Medical Writing Support shares more about his participation in MIT’s Hacking Medicine Grand Hack Weekend. As I mentioned in my last post, I was excited to participate in MIT’s Hacking Medicine Grand Hack. I paired up with two other attendees to develop and pitch our idea to theRead more

Dr. Thomas Laage,  Director, Product Development Consulting and Regulatory Medical Writing Support tells us about his experience with MIT’s Hacking Medicine Grand Hack Weekend. It started with an email from Dan Morden, a young biotech entrepreneur in Cambridge whom I had met during a business call several months ago. “MIT’s Hacking Medicine is holding aRead more

DURHAM, N.C., May 17, 2017 — Scott Millard, Premier Research’s head of analgesia strategic development, will speak on fibromyalgia clinical trials during a Town Hall Talk at the American Pain Society’s Annual Scientific Meeting, May 17-20 in Pittsburgh. Mr. Millard will present Operationalizing Clinical Trials in Fibromyalgia on Thursday, May 18, starting at 9:40 a.m.Read more

While there is currently no cure for atopic dermatitis (AD) — commonly called eczema — this prevalent condition can often be well managed through conventional drug therapies. Current AD strategies used by dermatologists include symptom relief, patient/parent education, and the prevention of secondary complications. The “Gold Standard” for Mild to Moderate Atopic Dermatitis The most frequently used therapiesRead more

When it comes to clinical trial participation, did you know: Almost one-third of all Phase III trials close early largely due to poor accrual. Poor accrual causes nearly one in 10 clinical trials in Phases II and III involving adults with cancer to never finish. Only one in four patients who are screened for inclusionRead more

Biologics have revolutionized psoriasis treatment over the last two decades. These targeted immunomodulatory therapies act directly on the cytokine pathways that are upregulated in psoriasis and other autoimmune diseases. Two major classes make up biologics in psoriasis treatment: tumor necrosis factor (TNF) inhibitors and interleukin (IL) inhibitors. TNF Inhibitors TNF inhibitors became the first available biologicRead more

A little less than five percent of the world’s population are estimated to suffer from more than 7,000 different types of known rare diseases. There are even more medical conditions where those who have them are too embarrassed to talk about what’s wrong or simply don’t know exactly what ails them. Yet, these individuals areRead more

No more posts
Phone Us Now
Email Us Now